BackAllogene Therapeutics Overview

Allogene Therapeutics Selling, General & Admin

Selling, General & Admin expenses for ALLO.

Quarterly SG&A Expenses

$14.09M
↓ 6.02% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$55.88M
↓ 11.2% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin